Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections.
mBio
; 13(4): e0199622, 2022 08 30.
Article
in English
| MEDLINE | ID: covidwho-1973798
ABSTRACT
The continuous emergence of SARS-CoV-2 variants with increased transmission and immune evasion has caused breakthrough infections in the vaccinated population. It is important to determine the threshold of neutralizing antibody titers (NT50) that permit breakthrough infections in humans. Here, we tested the neutralization titers of vaccinated patients who contracted Delta variant. All 64 patients with Delta breakthrough infections exhibited NT50 of less than 70. When the breakthrough sera were tested against USA-WA1/2020 (a strain isolated in late January 2020), 82.8%, 15.6%, and 1.6% of them had the NT50 ranges of <20, 20 to 50, and 50 to 69, respectively. When the same breakthrough sera were tested against Delta-spike SARS-CoV-2, 68.7%, 26.6%, and 4.7% of them had the NT50 ranges of <20, 20 to 50, and 50 to 69, respectively. Overall, the results suggest NT50 of 70 as a potential neutralizing threshold required to prevent Delta breakthrough infections. These clinical laboratory results have implications in vaccine strategy and public health policy. IMPORTANCE Given that neutralizing antibodies play a key role in protection of SARS-CoV-2 infection, it is important to define the neutralization levels in vaccinated individuals when they contracted breakthrough infections. In this study, we analyzed the neutralization levels from 64 vaccinated patients on days 0 to 5 before they tested positive for Delta breakthrough infections. The neutralization titers in these vaccinated individuals were all lower than 70 when they contracted breakthrough infections. The results suggest a neutralization titer of 70 as the potential threshold required to prevent breakthrough infections of Delta variant.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
MBio
Year:
2022
Document Type:
Article
Affiliation country:
Mbio.01996-22
Similar
MEDLINE
...
LILACS
LIS